SeqLL, Inc. (SQL)
| Market Cap | n/a |
| Revenue (ttm) | 329,495 |
| Net Income (ttm) | -1.05M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
SeqLL, Inc. has filed to go public with an IPO on the NASDAQ.
About SQL
SeqLL is an established life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields (e.g. genomics, proteomics, transcriptomics...). Our mission is to empower researchers with improved genetic tools that enable scientists and physicians to better understand the molecular mechanisms of disease and the underlying biological systems. We believe our proprietary sequencing technology platform has critical advantages over existing Next G... [Read more...]
| Industry Laboratory Analytical Instruments | IPO Date Pending |
| CEO Daniel Jones | Employees 8 |
| Stock Exchange NASDAQ | Ticker Symbol SQL |
Financial Performance
In 2020, SeqLL's revenue was $329,495, a decrease of -38.20% compared to the previous year's $533,129. Losses were -$1.05 million, -57.74% less than in 2019.